Results 1 to 10 of about 89,188,345 (129)

Safety of 3‐FL (3‐Fucosyllactose) as a novel food pursuant to Regulation (EU) 2015/2283 [PDF]

EFSA Journal, 2021
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3‐fucosyllactose (3‐FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch‐Ernst, John Kearney, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Thomas Frenzel, Marina Heinonen, Rosangela Marchelli, Monika Neuhäuser‐Berthold, Morten Poulsen, Miguel Prieto Maradona, Josef Rudolf Schlatter, Henk van Loveren, Paolo Colombo, Helle Katrine Knutsen   +26 more
doaj   +2 more sources

Safety of 3‐fucosyllactose (3‐FL) produced by a derivative strain of Escherichia coli K‐12 DH1 as a novel food pursuant to Regulation (EU) 2015/2283 [PDF]

EFSA Journal, 2023
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3‐fucosyllactose (3‐FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch‐Ernst, Alexandre Maciuk, Inge Mangelsdorf, Harry J. McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti, Margarita Aguilera‐Gómez, Francesco Cubadda, Thomas Frenzel, Marina Heinonen, Miguel Prieto Maradona, Rosangela Marchelli, Monika Neuhäuser‐Berthold, Morten Poulsen, Josef Rudolf Schlatter, Alexandros Siskos, Henk vanLoveren, Paolo Colombo, Estefanía Noriega Fernández, Helle Katrine Knutsen   +29 more
doaj   +2 more sources

Safety of 3‐fucosyllactose (3‐FL) produced by a derivative strain of Escherichia coli BL21 (DE3) as a Novel Food pursuant to Regulation (EU) 2015/2283 [PDF]

EFSA Journal, 2022
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3‐fucosyllactose (3‐FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch‐Ernst, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Thomas Frenzel, Marina Heinonen, Rosangela Marchelli, Monika Neuhäuser‐Berthold, Morten Poulsen, Miguel Prieto Maradona, Josef Rudolf Schlatter, Henk van Loveren, Paolo Colombo, Estefanía Noriega Fernández, Helle Katrine Knutsen   +27 more
doaj   +2 more sources

Obinutuzumab and Chemotherapy for Front-Line Treatment of Follicular Lymphoma Grade 3B and Composite Follicular Lymphoma: A Study of the Croatian Cooperative Group for Hematologic Diseases (KroHem) [PDF]

Pharmaceuticals
Background: Data on outcomes of follicular lymphoma grade 3B (FL gr.3B) and composite lymphoma (FL/large B-cell lymphoma (B-LCL)) are scarce and the effect of obinutuzumab is unknown. Patients and methods: We analyzed outcomes of patients with FL gr.3B &
Davor Galusic, Neno Zivkovic, Sandra Basic-Kinda, Barbara Dreta, Marija Ivic, Dino Dujmovic, Martina Moric-Peric, Hrvoje Holik, Neven Franjic, Jasminka Sincic-Petricevic, Ida Hude-Dragicevic, Igor Aurer   +11 more
doaj   +2 more sources

Safety of the extension of use of 3‐fucosyllactose (3‐FL) as a novel food pursuant to Regulation (EU) 2015/2283 [PDF]

EFSA Journal
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of the extension of use of 3‐fucosyllactose (3‐FL) as a novel food (NF) pursuant to ...
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline Castenmiller, Stefaan De Henauw, Ángeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Harry J. McArdle, Breige McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani, Frank Thies, Margarita Aguilera‐Gómez, Francesco Cubadda, Thomas Frenzel, Marina Heinonen, Helle Katrine Knutsen, Monika Neuhäuser‐Berthold, Morten Poulsen, Miguel Prieto Maradona, Josef Rudolf Schlatter, Alexandros Siskos, Henk vanLoveren, Estefanía Noriega Fernández, Paolo Colombo, Karen Ildico Hirsch‐Ernst   +28 more
doaj   +2 more sources

Regulation of hBD-2, hBD-3, hCAP18/LL37, and Proinflammatory Cytokine Secretion by Human Milk Oligosaccharides in an Organotypic Oral Mucosal Model

Pathogens, 2021
Human milk oligosaccharides (HMOs), the third largest solid fraction in human milk, can modulate inflammation through Toll-like receptor signaling, but little is known about their immunomodulatory potential in the oral cavity.
Ulvi K. Gürsoy, Krista Salli, Eva Söderling, Mervi Gürsoy, Johanna Hirvonen, Arthur C. Ouwehand   +5 more
doaj   +1 more source

Multi‐level metabolic engineering of Escherichia coli for high‐titer biosynthesis of 2′‐fucosyllactose and 3‐fucosyllactose

Microbial Biotechnology, 2022
Fucosyllactoses (FL), including 2′‐fucosyllactose (2′‐FL) and 3‐fucosyllactose (3‐FL), have garnered considerable interest for their value in newborn formula and pharmaceuticals.
Mengli Li, Chenchen Li, Yejiao Luo, Miaomiao Hu, Zhu Liu, Tao Zhang   +5 more
doaj   +1 more source

Statement on the Re-evaluation of 3,7-dimethylocta-1,5,7-trien-3-ol [FL-no: 02.146] based on additional data on a supporting substance [PDF]

EFSA Journal, 2012
In 2010 the CEF Panel concluded in its Opinion FGE.18Rev2 that for the substance 3,7-dimethylocta-1,5,7-trien-3-ol [FL-no: 02.146], no appropriate NOAEL was available in order to establish a margin of safety, and additional data were requested (90 days ...
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF)
doaj   +1 more source

Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT

Blood Cancer Journal, 2021
In multiple myeloma (MM), a high number of focal lesions (FL) detected using positron emission tomography/computed tomography (PET/CT) was found to be associated with adverse prognosis. To design a new risk stratification system that combines the Revised
Hee Jeong Cho, Sung-Hoon Jung, Jae-Cheol Jo, Yoo Jin Lee, Sang Eun Yoon, Sung-Soo Park, Do Young Kim, Ho-Jin Shin, Yeung-Chul Mun, Jun Ho Yi, Hyo Jung Kim, Da Jung Kim, Ho Sup Lee, Sung Hwa Bae, Chae Moon Hong, Shin Young Jeong, Jung-Joon Min, Sang Kyun Sohn, Chang-Ki Min, Kihyun Kim, Je-Jung Lee, Joon Ho Moon, The Korean Multiple Myeloma Working Party   +22 more
doaj   +1 more source

Methods for Phenotyping Adult Patients in Sepsis and Septic Shock: A Scoping Review

Critical Care Explorations, 2022
OBJECTIVE:. Despite its heterogeneous phenotypes, sepsis or life-threatening dysfunction in response to infection is often treated empirically.
Han Li, BS, Asena Markal, BS, Jeremy A. Balch, MD, Tyler J. Loftus, MD, Philip A. Efron, MD, Tezcan Ozrazgat-Baslanti, PhD, Azra Bihorac, MD   +6 more
doaj   +1 more source